EN DE
Watch Indoco Remedies Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Indoco Remedies Limited (INDOCO) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Indoco Remedies Limited stock ₹101, price ₹227, that is 55.7% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE873D01016

IR Indoco Remedies Limited logo Some data Nov 11, 2026

Indoco Remedies Limited

INDOCO · NSE

Far too expensive (fair value 56% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +8.7 %/yr in INR) 
Thin margins · 1.7% net margin (TTM) 
Moderate debt 
0.1% dividend yield · Token dividend
Some data 
Costs 66 times its yearly profit. 
Fair value ₹100.71 · Strongly overvalued 
Quality 37/100 
Negative free cash flow 
Trails peers (2/13) 
Narrow moat 20/100 · thin data
Watch Indoco Remedies Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹508.75 ₹163.86 Fair Value ₹100.71 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range ₹163.86 – ₹508.75 · fair‑value band ₹46.88 – ₹154.55 · the ₹227.14 price screens above the ₹100.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Indoco Remedies in your weekly email

Every Wednesday you see whether Indoco Remedies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally.

Show moreShow less

It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas.

The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc.

In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services.

Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering.

Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management.

The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Stock analysis

Indoco Remedies Limited (INDOCO) currently trades at ₹227.14, while our model-based Fair Value estimate is ₹100.71, 56% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at medium.

Scenario range: ₹46.88 (bear) to ₹154.55 (bull), the price of ₹227.14 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Indoco Remedies Limited reported revenue of ₹18.5B in FY2026 versus ₹15.0B in FY2022, a compound +5.3%/yr. Reported net income was −₹987M in FY2026.

Key figures

Market cap ₹20.2B (≈ $215M) Micro · P/E ratio 66.0 · P/S ratio 1.06 · EPS (TTM) ₹3.44 · Dividend yield 0.1% · Net margin 1.7% · Return on equity 3.2% · Return on assets (EBIT) 6.5% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −56%, INDOCO screens richer than that median.

Fair Value models

Bear ₹46.88 Fair Value ₹100.71 Bull ₹154.55
Price ₹227.14 · Downside -55.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹2.05 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ₹46.88 ₹100.71 ₹154.55 64
NCAV (Graham) ₹40.05 ₹53.66 ₹80.09 54
All 2 models by family
Multiples
EV/EBITDA ₹46.88 ₹100.71 ₹154.55 64
Asset-Based
NCAV (Graham) ₹40.05 ₹53.66 ₹80.09 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 27
Debt, balance sheet and risk of trouble
Investment 62
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 42
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 39
Distance to the 52-week high, does not count
New shares 68
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2021 (pandemic). Over 10 years: +6.3% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.6% (2021) → 0.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

INDOCO screens overvalued: fair value 56% below the price. Compare with Merck KGaA →

Compare Indoco Remedies Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 2/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −55.7% · Bottom 25%
Profitability
Return on equity (12 months) 3.2% · Below median
Return on assets −3.8% · Bottom 25%
Net margin (12 months) 1.7% · Below median
Operating margin (12 months) 2.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 7.3% · Above median
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.55× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 66.0× · Priciest 25%
P/B 2.15× · Pricier than median
P/S (12 months) 1.06× · Cheapest 25%
EV/EBITDA 19.3× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)37 · sector 28
PAST (return on equity)13 · sector 26
HEALTH (low debt)73 · sector 96
DIVIDEND (yield)2 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs INDOCO
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs INDOCO
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs INDOCO
Haleon plc HLN $9.20 $8.47 −8% vs INDOCO
Merck KGaA MRK €149.70 €108.83 −27% vs INDOCO
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs INDOCO
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs INDOCO
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs INDOCO
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs INDOCO
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs INDOCO

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Indoco Remedies Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Indoco Remedies Limited Fair Value". https://www.fairvalue-calculator.com/stock/INDOCO

Frequently asked questions

Is Indoco Remedies Limited (INDOCO) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹100.71 versus a price of ₹227.14, about 56% lower (overvalued).
What is the fair value of INDOCO?
Our model-based fair value for Indoco Remedies Limited is ₹100.71 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹227.14.
What is the quality score of INDOCO?
Indoco Remedies Limited has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Indoco Remedies Limited (INDOCO)?
Our model-based price target is the fair value of ₹100.71 (as of Nov 11, 2026) from 2 valuation models. Cautious scenario ₹46.88, optimistic scenario ₹154.55. It is a calculation from audited fundamentals, not an analyst target.
What is the Indoco Remedies Limited stock forecast for 2026?
Our models put fair value at ₹100.71, about 56% lower versus a price of ₹227.14 (overvalued). Cautious scenario ₹46.88, optimistic scenario ₹154.55. The calculation is refreshed regularly with new filings.
What is the revenue of Indoco Remedies Limited (INDOCO)?
Indoco Remedies Limited reported trailing-twelve-month revenue of about ₹19.1B (latest available figure, as of Nov 11, 2026).
Does Indoco Remedies Limited pay a dividend?
Indoco Remedies Limited currently shows a dividend yield of 0.09% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Indoco Remedies Limited (INDOCO) and when is the ex-dividend date?
Indoco Remedies Limited pays a dividend of ₹0.2 per share a year, a dividend yield of 0.1%. The last ex-dividend date was Sep 10, 2026. A dividend has been paid every year since at least 2005. The payout ratio is 5.8% of earnings. Our assessment: Token dividend. At a yield of 0.1% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.1% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Indoco Remedies Limited (INDOCO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Indoco Remedies Limited it is ₹100.71 per share (as of Nov 11, 2026), against a price of ₹227.14. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Indoco Remedies Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, INDOCO trades above its calculated fair value: price ₹227.14, fair value ₹100.71, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INDOCO?
No. The price is what the market pays today (₹227.14); the fair value is what the company's own numbers justify (₹100.71). For Indoco Remedies Limited the two are ₹126.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Indoco Remedies Limited worth?
The market values Indoco Remedies Limited at about ₹20.2B (market capitalisation, as of Nov 11, 2026). Per share that is ₹227.14; our models calculate a fair value of ₹100.71 per share.
What do the bullish and bearish scenarios say about INDOCO?
Our models span a range for Indoco Remedies Limited: cautious scenario ₹46.88, base ₹100.71, optimistic ₹154.55 per share (as of Nov 11, 2026, price ₹227.14). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INDOCO?
Indoco Remedies Limited trades at a price-to-earnings ratio of 66.0 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹100.71 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2017 to 2024), reported earnings: 29.8. Other multiples: P/B 2.2, P/S 1.1, EV/EBITDA 19.3.
How solid is the balance sheet of Indoco Remedies Limited (INDOCO)?
Balance-sheet figures for Indoco Remedies Limited (as of Nov 11, 2026): return on equity 3.2%, debt of 0.55 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is INDOCO from its 52-week high?
Indoco Remedies Limited trades at ₹227.14, about 17% below its 52-week high of ₹273.53 and 39% above the low of ₹163.86 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹100.71 is for.
Which stocks are comparable to Indoco Remedies Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Indoco Remedies Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹227.14, calculated fair value ₹100.71 (−56%), Quality Score 37/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INDOCO calculated?
We run Indoco Remedies Limited through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ₹100.71 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Indoco Remedies Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Indoco Remedies Limited (INDOCO)?
The closing price on Nov 16, 2026 was ₹227.14. Our model-based fair value is ₹100.71, about 56% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Indoco Remedies Limited right now?
The price sits above even our optimistic bull case (₹154.55). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (₹46.88 to ₹154.55). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Indoco Remedies Limited

How large is the market capitalisation of Indoco Remedies Limited (INDOCO)?
The market capitalisation of Indoco Remedies Limited is ₹20.2B (≈ $215M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Indoco Remedies Limited (INDOCO)?
The price-to-sales ratio of Indoco Remedies Limited is 1.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Indoco Remedies Limited (INDOCO)?
Earnings per share at Indoco Remedies Limited are ₹3.44 (price ÷ EPS = P/E 66.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Indoco Remedies Limited (INDOCO)?
The dividend yield of Indoco Remedies Limited is 0.1% (payout 5.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Indoco Remedies Limited (INDOCO)?
The net margin of Indoco Remedies Limited is 1.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Indoco Remedies Limited (INDOCO)?
The return on equity (ROE) of Indoco Remedies Limited is 3.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Indoco Remedies Limited (INDOCO)?
On an EBIT basis the return on assets of Indoco Remedies Limited is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Indoco Remedies Limited (INDOCO)?
The operating margin of Indoco Remedies Limited is 2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Indoco Remedies Limited (INDOCO)?
Revenue at Indoco Remedies Limited is growing 7.3% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Indoco Remedies Limited (INDOCO)?
Earnings per share at Indoco Remedies Limited are down 92.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Indoco Remedies Limited (INDOCO) generate?
The free cash flow of Indoco Remedies Limited is −₹1.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Indoco Remedies Limited (INDOCO) carry?
The net debt of Indoco Remedies Limited is ₹10.6B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Indoco Remedies Limited in the live analysis

One click puts Indoco Remedies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.